恶性肿瘤病史对具有择期修复指征的腹主动脉瘤患者长期生存的影响
该研究纳入2008至2021年单中心连续416例腹主动脉瘤在治疗范围内患者,评估实体瘤病史与长期生存的关系。117例有实体瘤病史,其中仅晚期癌症或正在治疗的非泌尿系实体瘤患者生存率较低(HR=1.84,P=0.04)。结论认为癌症病史通常不恶化腹主动脉瘤患者预后,但晚期或当前非泌尿系癌症患者需个体化决策。
要点
- 腹主动脉瘤患者总体预期寿命有限,既往癌症病史通常不恶化预后。
- 仅晚期癌症(转移或姑息治疗)或当前治疗的非泌尿系实体瘤患者生存率较低(HR=1.84,P=0.04)。
- 非晚期泌尿系癌症患者与无癌症患者生存率相似。
核心结论
- 腹主动脉瘤患者预期寿命有限,既往癌症病史通常不恶化其预后。
- 晚期癌症或当前治疗的非泌尿系实体瘤患者生存率较低,此类病例的腹主动脉瘤决策应个体化。
研究设计与样本
- 单中心连续病例系列,纳入2008至2021年就诊的腹主动脉瘤在治疗范围内的完整动脉瘤患者416例(平均年龄75.2岁;男性92.2%;314例择期治疗)。
- 采用Cox模型评估癌症病史与生存的关联,校正年龄、性别、Charlson合并症指数和动脉瘤治疗。
主要发现
- 416例中117例有实体瘤病史(61例泌尿生殖系、30例消化系、22例呼吸系),54例为活动性或治疗不足6个月,12例有转移,8例接受姑息治疗。
- 随访期间248例(59.6%)死亡。
- 非晚期泌尿系癌症患者生存率与无癌症患者相似。
- 仅晚期癌症(转移或姑息治疗)或当前治疗的非泌尿系实体瘤患者预期寿命较低(HR=1.84,P=0.04)。
- 所有腹主动脉瘤患者无论癌症病史如何,生存率均低于年龄和性别匹配人群。
临床怎么用
- 作者认为,对于晚期癌症或当前治疗的非泌尿系实体瘤的腹主动脉瘤患者,决策应个体化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The elective repair of aorto-iliac aneurysms (AAAs) in patients with a cancer history is sometimes controversial. Our aim was to evaluate the relationship between the history of a solid tumor and the long-term survival of patients with an AAA within therapeutic range. METHODS: The consecutive series of patients with an intact AAA within therapeutic range attended in a tertiary hospital (2008-2021) was evaluated. Collected variables included clinical and cancer characteristics, such as time since treatment, location, and extension. The association between cancer history and survival was evaluated with Cox models adjusted by age, sex, the Charlson comorbidity index, and aneurysm treatment. RESULTS: The study included 416 patients (mean age 75.2 years; 92.2% male; 314 AAA electively treated). Among them, 117 had a history of a solid tumor (61 genitourinary, 30 digestive, and 22 respiratory), 54 were active or treated <6 months, 12 had metastases, and 8 were under palliative care. During follow-up, 248 (59.6%) patients died. Patients with nonadvanced urological cancer had similar survival than those without cancer, while only those with an advanced cancer (metastasis or palliative care) or a currently treated nonurological solid tumor had lower life expectancy (hazard ratio = 1.84, P = 0.04). All AAA patients, regardless their cancer history, had lower survival rates when compared with an age- and sex-matched population. CONCLUSION: Patients with AAA have a limited life expectancy and a prior cancer history does not commonly worsen their prognosis. Patients with an advanced or a current nonurological cancer had lower survival rates, so in these cases AAA decision-making should be individualized.
引用
- Arpa A, Abadal M, Navarro N, et al. Influence of a History of Malignancy on the Long-Term Survival of Abdominal Aortic Aneurysm Patients with Indication for an Elective Repair. Ann Vasc Surg. 2025. PMID: 40054612. doi:10.1016/j.avsg.2025.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。